Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genotyping to determine cytochrome P450 2C9 (CYP2C9), P450 4F2 (CYP4F2), and vitamin K epoxide reductase subunit C1 (VKORC1) genetic variants for the purpose of managing the administration and dosing of warfarin, including use in guiding the initial warfarin dose to decrease time to a stable International Normalized Ratio (INR) and to reduce the risk of serious bleeding to be investigational.*

Background/Overview
Warfarin
Warfarin is administered to prevent and treat thromboembolic events (TEEs) in high-risk patients; warfarin dosing is a challenging process, due to the narrow therapeutic window, variable response to dosing, and serious bleeding events in 5% or more of patients (depending on definition). Patients are typically given a starting dose of 2 mg to 5 mg and frequently monitored with dose adjustments until a stable international normalized ratio (INR) value (a standardized indicator of clotting time) between 2 and 3 is achieved. During this adjustment period, a patient is at high risk of bleeding. Stable or maintenance warfarin dose varies among patients by more than an order of magnitude. Factors influencing stable dose include body mass index, age, interacting drugs, and indication for therapy.

Enzyme Variant Impact on Warfarin Metabolism
Warfarin, which is primarily metabolized in the liver by the cytochrome P450 2C9 (CYP2C9) enzyme, exerts an anticoagulant effect by inhibiting the protein vitamin K epoxide reductase complex, subunit 1 (VKORC1). Three single nucleotide variants, 2 in the CYP2C9 gene and 1 in the VKORC1 gene play key roles in determining the effect of warfarin therapy on coagulation. CYP2C9*1 metabolizes warfarin normally, CYP2C9*2 reduces warfarin metabolism by 30%, and
CYP2C9*3 reduces warfarin metabolism by 90%. Because warfarin given to patients with *2 or *3 variants will be metabolized less efficiently, the drug will remain in circulation longer, so lower warfarin doses will be needed to achieve anticoagulation. CYP2C9 and VKORC1 genetic variants account for approximately 55% of the variability in warfarin maintenance dose. Genome-wide association studies have also identified that a single nucleotide variant in the CYP4F2 gene has been reported to account for a small proportion of the variability in stable dose (the CYP4F2 gene encodes a protein involved in vitamin K oxidation). Studies have predicted that CYP4F2 variants explain 2% to 7% of the variability in warfarin dose in models, including other genetic and nongenetic factors.

Using the results of CYP2C9 and VKORC1 genetic testing to predict a warfarin starting dose that approximates a likely maintenance dose may benefit patients by decreasing the risk of serious bleeding events and the time to stable INR. Algorithms have incorporated not only genetic variation but also other significant patient characteristics and clinical factors to predict the best starting dose. Studies have compared the ability of different algorithms to predict a stable warfarin dose accurately. Currently, there does not appear to be a consensus for a single algorithm.

Several studies have examined associations between CYP2C9 and VKORC1 variants and warfarin dosing requirements in children.

There are different frequencies of variants related to warfarin pharmacokinetics across different races and ethnicities. Many of the original studies identifying associations between genes and prediction of warfarin dosing as well as studies developing algorithms were derived from cohorts composed largely of people of European descent. Evidence has suggested these algorithms do not perform as well in other ethnic groups. For example, CYP2C9*2 and CYP2C9*3 are not as useful in predicting warfarin dosing in African Americans, but other important variants have been identified such as CYP2C9*5, *6, *8, and *11. Studies have also identified new genetic variants and/or evaluated clinical genetic algorithms for warfarin dose in African American, Puerto Rican, Thai, Egyptian, Chinese, Japanese, Arabic, Turkish, African, Russian, and Scandinavian populations.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Several tests to help assess warfarin sensitivity, by determining the presence or absence of the relevant CYP2C9, VKORC1, and CYP4F2 variants, have been cleared by the U.S. Food and Drug Administration.
Administration (FDA) for marketing (Table 1). Similar tests also may be available as laboratory-developed services; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The tests are not identical regarding the specific variants and number of variants detected. Generally, such tests are not intended as stand-alone tools to determine optimum drug dosage but should be used with clinical evaluation and other tools, including the INR, to predict the initial dose that best approximates the maintenance dose for patients.

Table 1. FDA-Cleared Warfarin Tests

<table>
<thead>
<tr>
<th>Test (Laboratories)</th>
<th>Alleles Tested</th>
<th>Estimated Time to Completion, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>eSensor®† Warfarin Sensitivity Test (GenMark Dx)a</td>
<td>CYP2C9*2 and *3, VKORC1 1639G&gt;A</td>
<td>3-4</td>
</tr>
<tr>
<td>Rapid Genotyping Assay (ParagonDx)</td>
<td>CYP2C9*2 and *3, VKORC1 1173C&gt;T</td>
<td>Not reportedb</td>
</tr>
<tr>
<td>Verigene®‡ Warfarin Metabolism Nucleic Acid Test (Nanosphere)</td>
<td>CYP2C9*2 and *3, VKORC1 1173C&gt;T</td>
<td>≤2</td>
</tr>
<tr>
<td>Infiniti®‡ 2C9-VKORC1 Multiplex Assay for Warfarin (AutoGenomics)c</td>
<td>CYP2C9*2 and *3, VKORC1 1639G&gt;A</td>
<td>6-8</td>
</tr>
<tr>
<td>eQ-PCR™‡ LightCycler®‡ Warfarin Genotyping Kit (TrimGen)</td>
<td>CYP2C9*2 and *3, VKORC1 1639G&gt;A</td>
<td>≤2</td>
</tr>
</tbody>
</table>

Adapted from Cavallari et al (2011).
CYP2C9: cytochrome P450 2C9 enzyme; FDA: Food and Drug Administration; VKORC1: vitamin K epoxide reductase complex, subunit 1.
b Langley et al (2009) reported a turnaround time of 1.5 hours for the ParagonDx SmartCycler, which may be a precursor assay.
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022


The FDA (2007) approved updated labeling for Coumadin®‡ to include information on testing for gene variants that may help "personalize" the starting dose for each patient and reduce the number of serious bleeding events. The label was updated again in 2010. With each update, manufacturers of warfarin (Coumadin) were directed to add similar information to their product labels. The 2010 update added information on guiding initial dose by genotyping results for CYP2C9 and VKORC1, providing a table of genotypes and suggested initial dose ranges for each. However, suggested starting doses are also provided when genotyping information is unavailable, indicating that genetic testing is not required. Furthermore, the FDA did not include information on genetic variation in the label's black box warning on bleeding risk.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Using information about an individual's genotype may help in guiding warfarin dosing and could reduce the time to dose stabilization and selection of an appropriate maintenance dose that might avoid the consequences of too much or too little anticoagulation.

Summary of Evidence
For individuals with conditions requiring warfarin treatment who receive genotype-guided warfarin dosing, the evidence includes multiple randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are morbid events, medication use, and treatment-related mortality and morbidity. Thirty RCTs and 6 recent systematic reviews were identified. Most RCTs were single-center studies including fewer than 250 patients. Systematic reviews found the percentage of time the international normalized ratio (INR) was in therapeutic range was higher in patients treated with genotype-guided warfarin therapy; however, the heterogeneity between studies was high for this outcome. No RCT reported statistically significant differences in major bleeding, and only 1 reported
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

a significant reduction in thromboembolic events (TEEs) with genotype-guided dosing, but studies were not powered to show differences in these outcomes. Meta-analyses of RCTs found no difference between genotype-guided dosing and clinical dosing for mortality, and only 1 found reduction in TEEs, but genotype-guided dosing was associated with a lower risk of major bleeding. Very few trials enrolled sufficient numbers of subpopulations except White participants. In the Clarification of Optimal Anticoagulation through Genetics study, which included 27% African American participants, African Americans fared better in the clinically-guided group than in the genotype-guided group. One trial of elderly Chinese patients with atrial fibrillation experienced improved time with INR in the therapeutic range and a reduced risk of ischemic stroke, but no difference in bleeding events. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Supplemental Information**

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**American College of Medical Genetics**

In 2008, the American College of Medical Genetics policy statement on pharmacogenetic testing concluded: "There is insufficient evidence, at this time, to recommend for or against routine CYP2C9 and VKORC1 testing in warfarin-naive patients."

**American College of Chest Physicians**

In 2012, the ninth edition of the American College of Chest Physicians' evidence-based clinical practice guidelines on antithrombotic therapy and prevention of thrombosis stated: "For patients initiating VKA [vitamin K antagonist] therapy, we recommend against the routine use of pharmacogenetic testing for guiding doses of VKA (Grade 1B)." The updated 2021 guidelines make no mention of genotype-guided warfarin dosing.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

Clinical Pharmacogenetics Implementation Consortium
In 2017, the Clinical Pharmacogenetics Implementation Consortium updated guidelines for pharmacogenetics-guided warfarin dosing. The guideline provides recommendations for genotype-guided warfarin dosing to achieve a target international normalized ratio (INR) of 2 to 3 for adult and pediatric patients specific to continental ancestry. The guideline also states that "Although there is substantial evidence associating CYP2C9 and VKORC1 variants with warfarin dosing, randomized clinical trials have demonstrated inconsistent results in terms of clinical outcomes."

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
The Centers for Medicare & Medicaid Services (2009) published a national coverage determination on pharmacogenomic testing for warfarin response. The Centers for Medicare & Medicaid Services stated that "the available evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness improves health outcomes in Medicare beneficiaries outside the context of CED [coverage with evidence development], and is therefore not reasonable and necessary…"

However, the Centers also "believes that the available evidence supports that coverage with evidence development (CED) … is appropriate for pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness by any method, and is therefore covered only when provided to Medicare beneficiaries who are candidates for anticoagulation therapy with warfarin who:

1. Have not been previously tested for CYP2C9 or VKORC1 alleles; and
2. Have received fewer than 5 days of warfarin in the anticoagulation regimen for which the testing is ordered; and
3. Are enrolled in a prospective, randomized, controlled clinical study when that study meets [described] standards."

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.
Genotype-Guided Warfarin Dosing

Policy # 00245  
Original Effective Date: 12/16/2009  
Current Effective Date: 09/12/2022

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03479684</td>
<td>Randomized Trial of Genotype-guided Versus Standard for Warfarin Dosing</td>
<td>560</td>
<td>Dec 2020</td>
</tr>
<tr>
<td>NCT03797534</td>
<td>Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes: A Randomized Controlled Trial, Multi-Center Trial</td>
<td>600</td>
<td>Jan 2023</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01305148a</td>
<td>Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)</td>
<td>3800</td>
<td>Dec 2015 (suspended)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

a Denotes industry-sponsored or cosponsored trial.

References

Genotype-Guided Warfarin Dosing

Policy #: 00245  
Original Effective Date: 12/16/2009  
Current Effective Date: 09/12/2022

Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

Genotype-Guided Warfarin Dosing

Policy #  00245
Original Effective Date:  12/16/2009
Current Effective Date:  09/12/2022

Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022


Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022


Policy History
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022
12/04/2009 Medical Policy Committee approval
12/16/2009 Medical Policy Implementation Committee approval. New Policy
12/01/2010 Medical Policy Committee review
12/08/2011 Medical Policy Committee review
12/06/2012 Medical Policy Committee review
12/19/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/23/2013 Coding updated
12/12/2013 Medical Policy Committee review
12/18/2013 Medical Policy Implementation Committee approval. No change to coverage.
04/02/2015 Medical Policy Committee review
04/20/2015 Medical Policy Implementation Committee approval. No change to coverage.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
04/07/2016 Medical Policy Committee review
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

04/20/2016 Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
04/06/2017 Medical Policy Committee review
04/19/2017 Medical Policy Implementation Committee approval. No change to coverage.
08/01/2017 Coding update
02/06/2018 Coding update
04/01/2018 Coding update
05/03/2018 Medical Policy Committee review
05/16/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/09/2018 Medical Policy Committee review
08/15/2018 Medical Policy Implementation Committee approval. Investigational policy statement expanded to include genotyping for CYP4F2. Changed “polymorphisms” to “variants” in the investigational policy statement and throughout the policy. Title change to Genotype-Guided Warfarin Dosing.
08/01/2014 Medical Policy Committee review
08/14/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/06/2020 Medical Policy Committee review
08/12/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/05/2021 Medical Policy Committee review
08/04/2022 Medical Policy Committee review
08/10/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 08/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of...
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0030U, 81227, 81355</td>
</tr>
<tr>
<td>HCPCS</td>
<td>G9143</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genotype-Guided Warfarin Dosing

Policy # 00245
Original Effective Date: 12/16/2009
Current Effective Date: 09/12/2022

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.